MindRank Begins IND-enabling Studies of its first AI-designed Drug, 8 Months After Program Initiation

This is the second drug candidate that has entered the IND-enabling stage since the company's inception less than one year ago; MindRank has successfully delivered an allosteric inhibitor preclinical candidate (PCC) with best-in-class potential within a few months since the program initiated as a collaboration with a publicly traded biotech company, which started IND-enabling studies in September 2021. This is the second drug candidate that has entered the IND-enabling stage since the company's...

HANGZHOU, China, 18/01/2022 (informazione.news - comunicati stampa - scienza e tecnologia)

This is the second drug candidate that has entered the IND-enabling stage since the company's inception less than one year ago; MindRank has successfully delivered an allosteric inhibitor preclinical candidate (PCC) with best-in-class potential within a few months since the program initiated as a collaboration with a publicly traded biotech company, which started IND-enabling studies in September 2021 .

"Our platform has greatly improved the efficiency of drug discovery. We strive to push the boundaries of AI for drug discovery by continuous innovations," commented Zhangming Niu, Founder and CEO of MindRank

MindRank is an AI-driven biotech company. We hope to improve the efficiency and success rate of the drug discovery through creative integration it with AI. The company's ultimate goal is to find better drugs, treat more diseases, and help more patients.